Patents Assigned to Gador, S.A.
-
Patent number: 8952172Abstract: A new crystalline form of the Zoledronic acid, characterized by its X-rays diffractogram as well as by its spatial atomic distribution in the red crystalline and its curves of thermal analysis. There is also included a method to obtain this crystalline form, which includes the synthesis of the corresponding acid and the pharmaceutical composition this crystalline form comprises.Type: GrantFiled: February 4, 2010Date of Patent: February 10, 2015Assignee: Gador S.A.Inventors: Rafael Alberto Labriola, Dora Graciela Tombari, Adriana Vechhioli
-
Patent number: 8853187Abstract: The present invention relates to a composition for prevention and/or treatment of metabolic diseases of bones comprising at least one bisphosphonate; viscosity agents comprising carboxymethylcellulose and xanthan gum; at least one flavoring agent; and purified water; a process for preparing a composition according to the present invention; and use of such a composition for prevention, treatment and/or diagnosis of metabolic diseases of bones, especially for children.Type: GrantFiled: June 8, 2009Date of Patent: October 7, 2014Assignees: Gador S.A., University of LeidenInventors: Daniel Zanetti, Damian Cairatti, Enrique Piccinni, Emilio J. A. Roldan, Socrates Papapoulos
-
Patent number: 8338619Abstract: A method to obtain a new crystalline form of the Zoledronic acid, characterized by its X-rays diffractogram as well as by its spatial atomic distribution in the red crystalline and its curves of thermal analysis. There is also included a method to obtain this crystalline form, which includes the synthesis of the corresponding acid and the pharmaceutical composition this crystalline form comprises.Type: GrantFiled: February 4, 2010Date of Patent: December 25, 2012Assignee: Gador S.A.Inventors: Rafael Alberto Labriola, Dora Graciela Tombari, Adriana Vechhioli
-
Patent number: 8153648Abstract: The solid state chemistry of 17?-N-[2,5-bis(trifluoromethyl)phenyl]carbamoyl-4-aza-5-?-androst-1-en-3-one of which the international nonproprietary name is Dutasteride (the active ingredient in products marketed as Avodart, Avidart, Avolve, Duagen, Dutas, Dutagen, Duprost) and its process for preparing. The synthetic process comprises formation of the mixed anhydride, its subsequent reaction with 2,5-bis(trifluoromethyl)phenylamine in the presence of an appropriate Lewis catalyst and its isolation, purification and crystallization from acetonitrile/water.Type: GrantFiled: January 3, 2009Date of Patent: April 10, 2012Assignee: Gador S.A.Inventors: Dora Graciela Tombari, Constanza Pia Mangone, Maria Beatriz Garcia, Adriana Vechhioli, Rafael Alberto Labriola
-
Patent number: 7846474Abstract: This procedure consists in the first stage, of the administration of enough quantity of bisphosphonate preparation during the necessary period of time to acquire a degree of volumetric mineral density of the cortical tissue of application, within the normal range (average.+?.1 DS). Then the administration of the bisphosphonate preparation is interrupted in order to enable the development of the sectional momentum of inertia. The length of the second stage can be determined by means of a tomography. That is to say, that the periods of administration or non-administration of the mineralizing agent are defined or controlled by precise osteologic variables and therefore are not fixed. If during the second stage the cortical mineral density drops by 6-10% of the maximum value previously obtained, administration of bisphosphonate preparation should be resumed until the corresponding maximum adjusted value is reached again.Type: GrantFiled: January 18, 2008Date of Patent: December 7, 2010Assignee: Gador S.A.Inventors: Emilio J.A. Roldan, Anibal Perez-Lloret
-
Publication number: 20100197931Abstract: A new crystalline form of the Zoledronic acid, characterized by its X-rays diffractogram as well as by its spatial atomic distribution in the red crystalline and its curves of thermal analysis. There is also included a method to obtain this crystalline form, which includes the synthesis of the corresponding acid and the pharmaceutical composition this crystalline form comprises.Type: ApplicationFiled: February 4, 2010Publication date: August 5, 2010Applicant: Gador S.A.Inventors: Rafael Alberto Labriola, Dora Graciela Tombari, Adriana Vechhioli
-
Publication number: 20100197935Abstract: A method to obtain a new crystalline form of the Zoledronic acid, characterized by its X-rays diffractogram as well as by its spatial atomic distribution in the red crystalline and its curves of thermal analysis. There is also included a method to obtain this crystalline form, which includes the synthesis of the corresponding acid and the pharmaceutical composition this crystalline form comprises.Type: ApplicationFiled: February 4, 2010Publication date: August 5, 2010Applicant: GADOR S.A.Inventors: Rafael A. Labriola, Dora G. Tombari, Adriana Vecchioli
-
Publication number: 20090247491Abstract: The present invention relates to a composition for prevention and/or treatment of metabolic diseases of bones comprising at least one bisphosphonate; viscosity agents comprising carboxymethylcellulose and xanthan gum; at least one flavouring agent; and purified water; a process for preparing a composition according to the present invention; and use of such a composition for prevention, treatment and/or diagnosis of metabolic diseases of bones, especially for children.Type: ApplicationFiled: June 8, 2009Publication date: October 1, 2009Applicants: Gador S.A., University of LeidenInventors: Daniel Zanetti, Damian Cairatti, Enrique Piccinni, Emilio J.A. Roldan, Socrates Papapoulos
-
Publication number: 20090203724Abstract: The solid state chemistry of 17?-N-[2,5-bis(trifluoromethyl)phenyl]carbamoyl-4-aza-5-?-androst-1-en-3-one of which the international nonproprietary name is Dutasteride (the active ingredient in products marketed as Avodart, Avidart, Avolve, Duagen, Dutas, Dutagen, Duprost) and its process for preparing. The synthetic process comprises formation of the mixed anhydride, its subsequent reaction with 2,5-bis(trifluoromethyl)phenylamine in the presence of an appropriate Lewis catalyst and its isolation, purification and crystallization from acetonitrile/water.Type: ApplicationFiled: January 3, 2009Publication date: August 13, 2009Applicant: GADOR S.A.Inventors: Dora Graciela Tombari, Constanza Pia Mangone, Maria Beatriz Garcia, Adriana Vecchioli, Rafael Alberto Labriola
-
Patent number: 7560490Abstract: The present invention relates to a composition for prevention and/or treatment of metabolic diseases of bones comprising at least one bisphosphonate; viscosity agents comprising carboxymethylcellulose and xanthan gum; at least one flavoring agent; and purified water; a process for preparing a composition according to the present invention; and use of such a composition for prevention, treatment and/or diagnosis of metabolic diseases of bones, especially for children.Type: GrantFiled: January 23, 2001Date of Patent: July 14, 2009Assignees: GADOR S.A., University of LeidenInventors: Daniel Zanetti, Damian Cairatti, Enrique Piccinni, Emilio J. A. Roldan, Socrates Papapoulos
-
Publication number: 20090155358Abstract: This application refers to a modified-release pharmaceutical composition containing, as the active agent, a short-acting hypnotic agent or a pharmaceutically acceptable salt thereof, comprising two sustained-release pharmaceutical entities, differentiated from each other by a different release rate of the active agent wherein the release of the active agent from one of the entities starts before the release of the active agent from the second entity.Type: ApplicationFiled: December 5, 2006Publication date: June 18, 2009Applicant: Gador S.A.Inventors: Liliana Elisabeth Diaz, Gustavo Alejandro Andrade
-
Publication number: 20080227756Abstract: This procedure consists in the first stage, of the administration of enough quantity of bisphosphonate preparation during the necessary period of time to acquire a degree of volumetric mineral density of the cortical tissue of application, within the normal range (average.±.1 DS). Then the administration of the bisphosphonate preparation is interrupted in order to enable the development of the sectional momentum of inertia. The length of the second stage can be determined by means of a tomography. That is to say, that the periods of administration or non-administration of the mineralizing agent are defined or controlled by precise osteologic variables and therefore are not fixed. If during the second stage the cortical mineral density drops by 6-10% of the maximum value previously obtained, administration of bishphosphonate preparation should be resumed until the corresponding maximum adjusted value is reached again.Type: ApplicationFiled: January 18, 2008Publication date: September 18, 2008Applicant: Gador, S.A.Inventors: Emilio J. A. Roldan, Anibal Perez Lloret
-
Publication number: 20080090784Abstract: A new crystalline form of the Zoledronic acid, characterized by its X-rays diffractogram as well as by its spatial atomic distribution in the red crystalline and its curves of thermal analysis. There is also included a method to obtain this crystalline form, which includes the synthesis of the corresponding acid and the pharmaceutical composition this crystalline form comprises.Type: ApplicationFiled: August 10, 2007Publication date: April 17, 2008Applicant: Gador S.A.Inventors: Rafael Labriola, Dora Tombari, Adriana Vecchioli
-
Patent number: 7345183Abstract: The present invention is related to an oxime of the 13?-ethyl-17?-hydroxi-18,19-dinorpregn-4-en-20-in-3-o (norelgestromin) of Formula I with a relation of isomers E/Z between 1.3 and 1.6 and the method of producing the oxime.Type: GrantFiled: June 25, 2004Date of Patent: March 18, 2008Assignee: Gador S.A.Inventors: Dora Graciela Tombari, Adriana Vecchioli
-
Patent number: 6864228Abstract: This procedure consists in the first stage, of the administration of enough quantity of bisphosphonate preparation during the necessary period of time to acquire a degree of volumetric mineral density of the cortical tissue of application, within the normal range (average IDS). Then the administration of the bisphosphonate preparation is interruption in order to enable the development of the sectional momentum of inertia. The length of the second stage can be determined by means of a tomography. That is to say, that the periods of administration or non-administration of the mineralizing agent are defined or controlled by precise osteologic variables and therefore are not fixed. If during the second stage the cortical mineral density drops by 6-10% of the maximum value previously obtained, administration of bisphosphonate preparation should be resumed until the corresponding maximum adjusted value is reached again.Type: GrantFiled: May 12, 2000Date of Patent: March 8, 2005Assignee: Gador, S.A.Inventors: Emilio J. A. Roldan, Anibal Perez Lloret
-
Patent number: 6605603Abstract: The present invention relates to novel uses of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid or any of its soluble salts or any of its hydrates, in particular its use for the manufacture of a medicament for selective modulation of osteoblasts.Type: GrantFiled: July 27, 2001Date of Patent: August 12, 2003Assignees: Gador, S.A., University of LeidenInventors: Emilio J. A. Roldan, Anibal Perez-Lloret, Guillermo Vazquez, Ricardo Boland, Sokrates E. Papapoulos
-
Patent number: 6476223Abstract: An improved method for preparing N-[3(3-cyanopyrazole[1,5-a]pyrimidine-7-yl)phenyl]-N-ethyl-acetamide having the FORMULA I: in which the product in question is obtained in “a single step” starting with N-[3-[3-(dimethylamine)-1-oxo-2-propenyl]phenyl]acetamide (II) according to the following sequence: In a first stage N-[3-[3-(dimethylamine)-oxo-2-propenyl]phenyl]acetamide (II) is added in portions to a suspension of sodium hydride in dimethylformamide in the presence of ethyl iodide. The resulting suspension of compound (III) (N-[3-[3-(dimethylamine)-1-oxo-2-propenyl]phenyl]-N-ethyl-acetamide) is diluted with water until solution A is obtained which is used as it is. Subsequently, solution A is added to solution B of 3-amino-pyrazole-4-carbonitrile IV) in aqueous DMF/hydrochloric acid.Type: GrantFiled: December 10, 2001Date of Patent: November 5, 2002Assignee: Gador S. A.Inventors: Dora Tombari, Adriana Vecchioli
-
Patent number: 5990098Abstract: Use of 1-amino-3-N,N-dimethylamino)-propyliden-1,1-bisphosphonic acid of the structural formula: ##STR1## or of its monosodium or other pharmaceutically acceptable salt, as a biological carrier for bone active substances or for the preparation of a medicament for the diagnosis, prophylaxis and/or treatment of bone and/or mineral metabolism disorders.Type: GrantFiled: September 1, 1998Date of Patent: November 23, 1999Assignees: Gador, S.A., University of LeidenInventors: Ermond R. Van Beek, Clemens W. G. M. Lowik, Socrates Papapoulos, Rafael Labriola, Adriana Vecchioli
-
Patent number: 5885973Abstract: The present invention provides methods for bone mass anabolic preservation or augmentation in human or other animal subjects affected by osteoporosis or other metabolic bone disorder characterized by systemic or regional bone loss, using bisphosphonates formulations, wherein the bone mass anabolic composition contains effective non-toxic doses of ?3-(N,N-dimethylamine)-1-hydroxypropylidene!-bisphosphonic acid or olpadronate or the monosodium or other pharmaceutically acceptable salt thereof.Type: GrantFiled: October 10, 1997Date of Patent: March 23, 1999Assignees: Gador, S.A., University of LeidenInventors: Socrates Papapoulos, Jose Luis Ferretti, Rafael A. Labriola, Nelida Mondelo, Emilio J.A. Roldan